
Liminatus Pharma to be delisted from Nasdaq for failing market value rules, plans to appeal.
Liminatus Pharma received a delisting notice from Nasdaq due to failure to meet minimum market value requirements for its listed securities and publicly held shares. The company was given until May 18, 2026, to regain compliance but did not meet the ...

